PulseAGGREGATOR

Feed Stories Sources Features FAQs

PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Your news command center for 10,000+ sources. Search, filter, and set alerts — then cut through the noise with bias analysis, story clustering, and blindspot detection.

PR Newswire

prCenter

1h ago

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosistranslating…

– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has…

Factuality

70/100

Political Bias

Center

Ownership

Cision

Country

USA

Region

North America

Language

English

Keywords#Karyopharm#Application#Drug#Drug Application#FDA

Read Original ↗

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis | Pulse Aggregator